What is ImmunityBio, Inc.'s stock issuance proceeds?

ImmunityBio, Inc. (IBRX) reported stock issuance proceeds of $971K in Q1 2026.

How has ImmunityBio, Inc.'s stock issuance proceeds changed year-over-year?

ImmunityBio, Inc.'s stock issuance proceeds increased by 341.4% year-over-year, from $220K to $971K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

ImmunityBio, Inc. IBRX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co.MRK

$157M+726%

Gilead SciencesGILD

$166M-34.1%

Summit TherapeuticsSMMT

$3.8M+88.1%

Immunovant, Inc.IMVT

——

Kymera TherapeuticsKYMR

——

Protagonist TherapeuticsPTGX

——

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s stock issuance proceeds?: ImmunityBio, Inc. (IBRX) reported stock issuance proceeds of $971K in Q1 2026.
How has ImmunityBio, Inc.'s stock issuance proceeds changed year-over-year?: ImmunityBio, Inc.'s stock issuance proceeds increased by 341.4% year-over-year, from $220K to $971K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.